medtronic carelink programator-2090, medtronic carelink analizator-2290 i glava za programiranje-2067/2067l
medic d.o.o., zagreb - programiranje medtronic i vitatron implantabilnih uređaja
betaject lite
bayer d.o.o., zagreb - automatski injektor za primjenu predhodno napunjene štrcaljke koja sadrži lijek betaferon 250 mikrograma/ml praška i otapalo za
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorida)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorida)
citeral 500 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - ciprofloksacin - film tableta - 500 mg/1 tableta - 1 film tableta sadrži: 500 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorid, monohidrata)
citeral 250 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo, isevića sokak 6, sarajevo - ciprofloksacin - film tableta - 250 mg/1 tableta - 1 film tableta sadrži: 250 mg ciprofloksacin (u obliku ciprofloksacinhidrohlorid, monohidrata)
citeral 500 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo - ciprofloksacin - film tableta - 500 mg/1 tableta - 1 film tableta sadrži: 500 mg ciprofloksacina (u obliku ciprofloksacinhidrohlorid, monohidrata)
citeral 250 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo - ciprofloksacin - film tableta - 250 mg/1 tableta - 1 film tableta sadrži: 250 mg ciprofloksacina (u obliku ciprofloksacinhidrohlorid, monohidrata)
cipromed 500 mg/1 tableta filmom obložena tableta
pliva d.o.o.sarajevo - ciprofloksacin - filmom obložena tableta - 500 mg/1 tableta - 1 filmom obložena tableta sadrži: 500 mg ciprofloksacina (u obliku ciprofloksacinhidrohlorida)
xtandi
astellas pharma europe b.v. - enzalutamide - prostatske neoplazme - endokrinska terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.